Home » Topics » BioWorld Science

BioWorld Science
RSS

New compounds for Huntington's disease presented by PTC Therapeutics

Jan. 20, 2020

Meiji Seika Pharma describes new PDE4 inhibitors

Jan. 20, 2020

AlzeCure Pharma presents Trk-A and/or Trk-B and/or Trk-C modulators

Jan. 20, 2020

Single transcription factor enables chronic toxoplasma infection

Jan. 20, 2020

B cells help T cells succeed during checkpoint blockade

Jan. 20, 2020

Roche discloses new EGFR mutant inhibitors

Jan. 20, 2020

Suzhou Mednes Pharma Tech patents hedgehog signaling inhibitors

Jan. 20, 2020

ASIT Biotech publishes phase III data for gp-ASIT+ grass allergen peptide immunotherapy

Jan. 20, 2020

OXi-4503 in combination with ARA-C shows safety and early clinical efficacy in AML

Jan. 20, 2020

Novel muraminomicin derivatives with potent activity in MRSA infection models

Jan. 20, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...